Aspirin in Established MASLD/MASH: protocol for a systematic review and meta-analysis of effectiveness and safety

Read full text Summarise with VIRAT
Authors: Vittorio De Vita, Tommaso Dionisi, Giovanni Addolorato, Luca Miele
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This preregistration covers a systematic review and, where appropriate, meta-analysis of aspirin use and outcomes among adults with established metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis (MASLD/MASH; legacy NAFLD/NASH terms included). The review excludes general-population prevention studies and focuses on patients with disease already present at baseline. Critical outcomes are incident HCC, major liver outcomes/decompensation, liver-related mortality, all-cause mortality, major bleeding, and longitudinal fibrosis progression/regression. Supportive outcomes include steatosis, activity/histology metrics, MACE, and other safety outcomes. Searches will be run from inception in PubMed/MEDLINE, Embase, CENTRAL, Scopus, and Web of Science without date limits. RoB 2, ROBINS-I, and GRADE will be used. Quantitative synthesis will only be undertaken when studies are sufficiently comparable within the same outcome family, estimand, and design stream.

Fields of Study & Subjects

Liver Disease Diagnosis and Treatment Hepatocellular Carcinoma Treatment and Prognosis Drug-Induced Hepatotoxicity and Protection

Publication details

Publication date
1 January 2026
Language
EN
Document type
Preprint